Table 3.
Early pregnancy endogenous hormones and breast cancer risk for a doubling of hormone concentration, by ER/PR status: Northern Sweden Maternity Cohort
| Overall | ER–/PR– | ER+/PR+ | p het | |
|---|---|---|---|---|
| Estradiol | 220/404 | 50/89 | 152/282 | |
| 1.19 (0.94–1.50) | 1.35 (0.78–2.32) | 1.08 (0.81–1.43) | 0.18 | |
| Free estradiol | 210/374 | 49/86 | 143/258 | |
| 1.02 (0.80–1.29) | 1.09 (0.59–2.02) | 0.95 (0.72–1.27) | 0.31 | |
| Estrone | 222/410 | 50/90 | 154/286 | |
| 1.08 (0.89–1.30) | 1.20 (0.77–1.88) | 0.97 (0.78–1.22) | 0.13 | |
| Testosterone | 221/407 | 50/90 | 153/283 | |
| 1.33 (1.02–1.74) | 0.82 (0.47–1.43) | 1.57 (1.13–2.18) | 0.05 | |
| Free testosterone | 211/377 | 49/87 | 144/260 | |
| 1.08 (0.88–1.33) | 0.66 (0.40–1.08) | 1.31 (1.02–1.68) | <0.01 | |
| Progesterone | 221/406 | 50/90 | 153/282 | |
| 0.94 (0.67–1.34) | 1.61 (0.77–3.36) | 0.64 (0.41–1.00) | 0.01 | |
| SHBG | 212/384 | 49/89 | 145/264 | |
| 1.19 (0.95–1.50) | 1.47 (0.90–2.40) | 1.05 (0.80–1.38) | 0.10 |
Data presented as number of cases/controls and ORlog2 (95% CI)
Conditional logistic regression controlling for gestational age at blood collection (continuous). p het between ER+/PR+ and ER–/PR– breast cancer subtypes assessed using a likelihood ratio test comparing models assuming the same association between the hormones and breast cancer overall to one assuming different associations by subtype
CI confidence interval, ER estrogen receptor, OR odds ratio, PR progesterone receptor, SHBG sex hormone binding globulin